Molecular Medicine and Diagnostics

Biography

Biography: Cuilan Li

Abstract

Nowadays, two members were found at Golph3 family, Golph3 and its paralogue Golph3L. Golph3 has recently been reported to involve in the clinical progression in several human cancers including ovarian cancer. However, the expression status and function of Golph3L were rarely reported. We explored the expressions of Golph3 and Golph3L in ovarian cancer and their relationship with the disease. Methods: The expressions level of Golph3 and Golph3L were detected by ELISA, quantitative PCR (Q-PCR), western blot (WB) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal, borderline tissues and also correlated with clinicopathological parameters. Results: No detectable Golph3 and Golph3L expression in serum. A continuous up regulation of Golph3 and Golph3L in the order of normal, borderline and malignant tissues was observed by Q-PCR, western-blot and IHC detection. Statistical analysis based on IHC detection showed significant difference (P<0.001 & P<0.05). Univariate and multivariate analysis indicate that overexpression of Golph3 and Golph3L are associated with clinical stage (P=0.006, P=0.03), T classification (P=0.07, P=0.04), N classification (P=0.02, P=0.03), chemo-sensitivity (P=0.045, P=0.045), tumor-free survival (P=0.014, P=0.034) and overall survival time (P=0.023, P=0.037). Univariate and multivariate analysis showed that Golph3 and Golph3L overexpression were, respectively, independent prognostic factor in ovarian cancer. Kaplan-Meier analysis revealed that patients with Golph3 and/or Golph3L over-expression experienced significantly disease-free and much shorter overall survival time (log-rank P<0.001 & P<0.05). Conclusions: Both Golph3 and Golph3L were over-expression in ovarian cancer. Correlations with clinical parameters suggested that Golph3 and Golph3L are both independent prognostic factors for ovarian cancer.